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Added value of speckle tracking in the evaluation of cardiac
function in patients with sickle cell disease
Speckle tracking echocardiography is a new means of evalu-
ating cardiac function. The principle of speckle tracking is to
measure myocardial strain, based on local shortening, length-
ening and thickening of the muscles.
It has been proposed that the left ventricle global longitu-
dinal strain (LV-GLS) could be a useful tool for the detection
of early systolic dysfunction in patients under cardiotoxic
chemotherapy (Thavendiranathan et al, 2014). Moreover, the
high reproducibility of the LV-GLS represents an advantage
over the left ventricle ejection fraction (LVEF) (King et al,
2016; Medvedofsky et al, 2017). Compared to the LVEF, the
LV-GLS is less affected by changes in loading conditions,
which makes it a potentially useful tool in patients with
sickle cell disease (SCD), due to the chronic overload associ-
ated with SCD. However, in this population, studies are rare
and results are conflicting (Ahmad et al, 2012; Sengupta
et al, 2012; Barbosa et al, 2014; Hammoudi et al, 2014).
The primary aim of our study was to determine whether
the LV-GLS was abnormal in a monocentric population of
adults with SCD, compared to a matched population of
healthy individuals. The secondary aim was to investigate
correlations between the echocardiographic parameters and
the biological and clinical evaluations of patients with SCD.
The institutional Ethics Committee approved the protocol.
All patients provided informed consent.
We prospectively included 37 patients with SCD and 34
healthy, age- and sex-matched controls. The patient and con-
trol groups were similar in age (31  10 years vs.
32  10 years, respectively).
The LVEF was significantly lower in the SCD group than
in the control group (Teicholz: 618% vs. 676%; P = 005;
Simpson: 619% vs. 693%; P < 005; Table I). However, only
one patient had a Simpson LVEF < 50%. The left ventricular
(LV) mass and LV end diastolic diameter (LVEDD) were
higher in the patient group (LV mass: 107 g/m2 vs. 70 g/m2,
P < 005 and LVEDD: 53 mm vs. 46 mm; P < 005). The
myocardial performance index was higher (higher values
indicate impaired LV function) in the patient group com-
pared to the control group (038 vs. 027; P < 005). The
LV-GLS was significantly lower in the SCD group than in
the control group (194% vs. 224%; P < 005), and it
was abnormal (strain > 18%) in 8 (21%) patients of the
SCD group. Diastolic function was abnormal in three SCD
patients (8%), but normal in the entire control group. The
tricuspid regurgitation velocity was higher in the SCD group
than in the control group (224 m/s vs. 196 m/s, P < 005).
However, no patient had pulmonary hypertension.
The multivariate analysis results (Table II) showed that
only the LV-GLS and LVEDD remained significantly different
between groups.
Among patients with SCD, the mean Hb was 94 g/l
(range: 61–122 g/l) and the mean HbF was 127% (range: 1–
286%). The mean ferritin level was 644 lg/l (range: 13–
7267 lg/l). Iron overload, defined as a ferritin level greater
than 1000 lg/l, was observed in five patients. The mean N-
terminal pro b-type natriuretic peptide (NTproBNP) level
was 154 pg/ml (range 12–1685 pg/ml). The mean patient
walking distance was 66% of the predicted value (range:
33–88%).
Table I. Univariate analysis results show differences between SCD
and healthy controls.
Parameter Control SCD P
LVEF-Teicholz (%) 676  69 618  62 <005
LVEF-Simpson (%) 693  53 619  72 <005
LVEF < 50% 0 1 (27%)
MPI 027  008 038  12 <005
LV-GLS (%) 224  28 194  24 <005
LV-GLS < 18% 0 8 (21%)
TRV (m/s) 196  021 224  025 <005
E/A 163  035 157  04 NS
E0 (m/s) 016  003 015  004 NS
E/E0 564  134 644  176 NS (0054)
DT (ms) 187  36 194  37 NS
Diastolic
dysfunction
0 3 (8%) NS
LVEDD (mm) 46  49 53  51 <005
LV mass (g/m2) 70  28 107  45 <005
LVH 0 18 (48%) <005
Results are expressed as the mean  standard deviation.
DT, deceleration time of E mitral wave; E0, early diastolic mitral
annular tissue Doppler velocity; E/A, early peak diastolic velocity of
the mitral inflow/late peak diastolic velocity of the mitral inflow; E/
E0, ratio between peak velocities of mitral E wave and early-diastolic
mitral annulus; LV mass, left ventricular mass; LV-GLS, left ventricle
global longitudinal strain; LVEDD, left ventricular end-diastolic
diameter; LVEF, left ventricular ejection fraction; LVH, left ventricu-
lar hypertrophy; MPI, myocardial performance index; NS, not signif-
icant; SCD, sickle cell disease; TRV, maximal tricuspid regurgitation
velocity.
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A correlation was found between the ferritin level and the
LVEF (P = 004) and the LVEF and LV-GLS (P = 0027). No
correlation was found between NTproBNP level and LVEF
(P = 0569) NTproBNP and LV-GLS (P = 0859), walking
distance test and LVEF (P = 02) and walking distance test
and LV-GLS (P = 0106).
Our study showed that GLS was a more powerful index of
systolic function than LVEF in patients with SCD. Indeed,
the GLS was abnormal in 8 (21%) of 37 patients; in contrast,
the LVEF was abnormal in only one of these patients. We
could not find a correlation between LV-GLS and the walk-
ing distance test or the NTproBNP level. The small number
of patients included in the study might explain these results.
Furthermore, walking distance test can also be influenced by
anaemia, as could be NTproBNP level (Karakoyun et al,
2017).
We conclude that the LV-GLS, an emerging sensitive and
reproducible parameter of systolic function, appeared to be
an effective tool for the detection of early systolic dysfunc-
tion in patients with SCD.
However, the clinical impact of an altered LV-GLS in
patients with SCD remains to be assessed: larger studies, with
a longer follow-up, should be conducted to confirm our
results and to evaluate whether LV-GLS might have prognos-
tic implications and whether it should be recommended in
routine evaluations of these patients.
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A significant proportion of children of African descent with
HbSb0 thalassaemia are inaccurately diagnosed based on
phenotypic analyses alone
Two sickle cell disease (SCD) phenotypes, HbSS and HbSb0
thalassaemia, are believed to be so similar in disease severity
that all major paediatric National Institute of Health ran-
domized controlled trials include both (Wang et al, 2011;
DeBaun et al, 2014; Brousseau et al, 2015). However, data
from our group and others suggest the two diagnoses are
associated with different clinical courses (Serjeant et al, 1979;
Zago et al, 1980), highlighting the importance of accurately
distinguishing the two. In a cross-sectional study, we tested
two hypotheses: (i) a subset of phenotypic diagnoses of
HbSb0 thalassaemia and HbSS are discordant with their
genotypic diagnoses; and (ii) phenotypic misclassification of
HbSb0 thalassaemia is associated with alpha-chain deletions.
We used data from the multicentre Silent Cerebral Infarct
Transfusion (SIT) Trial (DeBaun et al, 2014). Individuals
aged 5–15 years with HbSS or HbSb0 thalassaemia by prior
high-performance liquid chromatography (HPLC), isoelectric
focusing (IEF), or DNA sequencing were eligible. Two Texas
sites incorporated DNA sequencing into routine state new-
born screening, while the other 27 sites used HPLC/IEF with
laboratory parameters. At all sites, red blood cell (RBC)
indices (mean cell volume [MCV] measurements and RBC
counts) and HbA2 percentages were obtained at screening.
DNA sequencing was performed or repeated on all samples
at the Centers for Disease Control and Prevention (CDC)
(Bean et al, 2014). All samples were run on an ABI 3730
DNA Analyzer, and sequences were reviewed using Sequenc-
ing Analysis 5.2 (Applied Biosystems, Inc., Foster City, CA,
USA). Polymerase chain reaction techniques (Bean et al,
2012) determined the number of alpha-chain deletions on all
participants. Informed consent and Institutional Review
Board approval were obtained.
We defined “phenotypic diagnosis” as a diagnosis through
HPLC/IEF with laboratory parameters (RBC indices and
HbA2 percentages). We defined “genotypic diagnosis” as a
diagnosis through DNA sequencing, and “phenotypic misclas-
sification” as discordant phenotypic and genotypic diagnoses.
We performed two analyses: (i) phenotypic diagnoses at
study entry were compared to diagnoses from CDC genotyp-
ing; (ii) newborn genotypic diagnoses from Texas sites were
compared to CDC genotypic diagnoses. Diagnoses with and
without phenotypic misclassification were compared to par-
ticipant characteristics with Mann-Whitney U-tests. An exact
McNemar test assessed the paired phenotypic diagnosis of
Table I. Comparison of those with and without phenotypic misclas-
sification of HbSb0 thalassaemia (n = 53) and HbSS (n = 698) based






HbSS 6 (09%) 692 (991%) <0001*
HbSb0 thalassaemia 39 (736%) 14 (264%)
HbSb0 thalassaemia phenotype
Alpha chain deletions 0119‡
2 alpha-chain
deletions
11 (282%) 1 (71%)
1 alpha-chain
deletion
13 (333%) 5 (357%)
0 alpha-chain
deletions
15 (385%) 8 (571%)
Totals 39 14
Blood indices†
Mean cell volume 7200 (1250) 7035 (530) 0793‡
HbA2 percentage 438 (100) 470 (125) 0639‡
Red blood cell count 330 (110) 390 (095) 0005‡
HbSS phenotype
Alpha chain deletions 0628‡
2 alpha-chain
deletions
0 (00%) 28 (40%)
1 alpha-chain
deletion
2 (333%) 262 (379%)
0 alpha-chain
deletions
4 (667%) 402 (581%)
Totals 6 692
Blood indices†
Mean cell volume 696 (3173) 839 (950) 0173‡
HbA2 percentage 45 (350) 30 (100) 0067‡
Red blood cell count 335 (125) 27 (068) 0039‡
*Exact McNemar test.
†Median (interquartile range) for each value given.
‡Mann-Whitney U-Test.
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